Naxitamab

Buy Danyelza (Naxitamab-gqgk) Injection in India
Generic Name/API:Naxitamab-gqgk
Packaging:Danyelza is supplied as a 40 mg/10 mL (4 mg/mL) single-dose vial for intravenous infusion.
Storage:Store it refrigerated at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light until time of use.
Dosage:For dosage information, please visit the General Information section.
Strength:Injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial.
Indication:Danyelza is indicated in combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

DANYELZA (Naxitamab-gqgk) is a GD2-binding monoclonal antibody, used in combination with a medicine called granulocyte-macrophage colonystimulating factor (GM-CSF) to treat children 1 year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that: 

  • has come back (relapsed) or that did not respond to previous treatment (refractory), and 
  • has shown a partial response, minor response, or stable disease to prior therapy. 

Strength: 

Injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial. 

Dosage: 

The recommended dosage of DANYELZA is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on Days 1, 3, and 5 of each treatment cycle. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks. 

Discontinue DANYELZA and GM-CSF for disease progression or unacceptable toxicity. Administer GM-CSF subcutaneously prior to and during each treatment cycle as recommended. 

Adverse Effects:

  • Infusion-related reaction
  • Pain
  • Tachycardia
  • Vomiting
  • Cough
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Hypertension
  • Fatigue
  • Erythema multiforme
  • Peripheral neuropathy
  • Urticaria
  • Pyrexia
  • Headache
  • Injection site reaction
  • Edema
  • Anxiety
  • Localized edema
  • Irritability 

Storage:

Store it refrigerated at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light until time of use. 

  • Serious Infusion-Related Reactions: 

Patients receiving Danyelza can cause serious Infusion-related reactions that include hypotension, bronchospasm, hypoxia, and stridor. Premedicate with an antihistamine, acetaminophen, an H2 antagonist and corticosteroid as recommended. Monitor patients closely for signs and symptoms of infusion reactions during and for at least 2 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Reduce the rate, interrupt infusion, or permanently discontinue medication based on severity and institute appropriate medical management as needed. 

  • Neurotoxicity:

Danyelza may cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). 

    • Pain – Administer intravenous opioids as needed for breakthrough pain. Permanently discontinue Danyelza based on severity of the pain.
    • Transverse myelitis – Permanently discontinue Danyelza in these symptoms.
    • RPLS – Monitor blood pressure during and following Danyelza infusion and assess for neurologic symptoms. Permanently discontinue the medication in case of symptomatic RPLS.

Permanently discontinue medication based on severity of peripheral neuropathy, severity of the neurological disorders of the eye and in patients with urinary retention that does not resolve following discontinuation of opioids.

  • Myocarditis:

Myocarditis may occur in adolescent patients who receive Danyelza. Monitor for signs and symptoms of myocarditis during treatment with Danyelza. Withhold, reduce the dose, or permanently discontinue medication based on severity.

  • Hypertension:  

Use of danyelza is associated with risk of hypertension. Monitor blood pressure during infusion, and at least daily on Days 1 to 8 of each cycle of medication and evaluate for complications of hypertension including RPLS. Interrupt Danyelza infusion and resume at a reduced rate, or permanently discontinue medication based on the severity.

  • Orthostatic Hypotension: 

In patients taking Danyelza, the symptoms of orthostatic hypotension may occur. Monitor postural blood pressure prior to initiating treatment with Danyelza and as clinically indicated with subsequent dosing. Withhold, reduce dose, or permanently discontinue Danyelza based on severity.

Process to Import Medicine

FAQ

Danyelza (Naxitamab-gqgk) has a most important active ingredient called Naxitamab-gqgk which targets a protein on cancer cells and signals the body’s immune system to kill it.

It is used for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. It is used in combination with granulocyte-macrophage colony-stimulating factor (GMCSF).

Infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability are the most common ones.

No, it is not advisable for the patients with a history of severe hypersensitivity reaction to naxitamab-gqgk. Reactions have included anaphylaxis.

The price of Danyelza (Naxitamab-gqgk) Injection in India may vary based on currency fluctuations and import duties. For pricing details, contact 247QualityMeds at +91-9967979080.

To buy Danyelza (Naxitamab-gqgk) in Delhi, provide a valid prescription and required patient details to initiate the medicine procurement process.

You can buy Danyelza (Naxitamab-gqgk) Injection online in India with a valid prescription. Submit an enquiry to 247QualityMeds to initiate the prescription-based purchase process. Danyelza is a prescription medicine administered by intravenous infusion.

Related products